TISIDB

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Multi-pass membrane protein
Domain	PF02816 Alpha-kinase family PF00520 Ion transport protein PF16519 Tetramerisation domain of TRPM
Function	Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental process that adjusts plasma membrane divalent cation fluxes according to the metabolic state of the cell. Phosphorylates annexin A1 (ANXA1).

> Gene Ontology [ TOP ]
Biological Process	GO:0006816 calcium ion transport GO:0006875 cellular metal ion homeostasis GO:0007160 cell-matrix adhesion GO:0010960 magnesium ion homeostasis GO:0010961 cellular magnesium ion homeostasis GO:0016340 calcium-dependent cell-matrix adhesion GO:0031032 actomyosin structure organization GO:0031589 cell-substrate adhesion GO:0046777 protein autophosphorylation GO:0051259 protein oligomerization GO:0051262 protein tetramerization GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0097300 programmed necrotic cell death
Molecular Function	GO:0003779 actin binding GO:0004674 protein serine/threonine kinase activity GO:0005216 ion channel activity GO:0005261 cation channel activity GO:0005262 calcium channel activity GO:0015085 calcium ion transmembrane transporter activity GO:0015267 channel activity GO:0017022 myosin binding GO:0022803 passive transmembrane transporter activity GO:0022838 substrate-specific channel activity GO:0046873 metal ion transmembrane transporter activity GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component	GO:0001726 ruffle GO:0031252 cell leading edge

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04621 NOD-like receptor signaling pathway hsa04978 Mineral absorption
Reactome	R-HSA-983712: Ion channel transport R-HSA-2672351: Stimuli-sensing channels R-HSA-3295583: TRP channels R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TRPM7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TRPM7 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 3	Resistant to T-cell proliferation

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TRPM7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.424	0.193
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.831	0.531
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.125	0.903
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.034	0.896
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.272	0.909
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.265	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.084	0.823
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.33	0.857
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.189	0.926
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.314	0.777
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.164	0.454
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.075	0.137

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TRPM7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	6.8	4.3	0.443
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	8.5	2.6	0.702
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRPM7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRPM7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRPM7. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRPM7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TRPM7 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TRPM7 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TRPM7
Name	transient receptor potential cation channel, subfamily M, member 7
Aliases	CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TRPM7 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting TRPM7.

ID	Name	Drug Type	Targets	#Targets
DB04395	Phosphoaminophosphonic Acid-Adenylate Ester	Small Molecule	ACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......	26
DB04447	1,4-Dithiothreitol	Small Molecule	ALDH1A1, AXIN1, CAMK2A, GSTZ1, HMGCR, LGALS1, MSRA, PPIB, TPI1, TR ......	10

Browse TRPM7